Summary of mutation analysis in CML patients according to imatinib response
| Imatinib response (at study) . | Total no. of patients . | No. (%) with kinase domain mutation . | No. (%) with regulatory domain mutation . |
|---|---|---|---|
| Nonresponder | 38 | 13 (34) | 0 (0) |
| CCyR | 38 | 9 (24) | 5 (13) |
| Relapse | 22 | 7 (32) | 2 (9) |
| Total | 98 | 29 (30) | 7 (7) |
| Imatinib response (at study) . | Total no. of patients . | No. (%) with kinase domain mutation . | No. (%) with regulatory domain mutation . |
|---|---|---|---|
| Nonresponder | 38 | 13 (34) | 0 (0) |
| CCyR | 38 | 9 (24) | 5 (13) |
| Relapse | 22 | 7 (32) | 2 (9) |
| Total | 98 | 29 (30) | 7 (7) |